Point Biopharma’s closely watched prostate cancer radiopharmaceutical study disappoints, Lilly again extends offer
Point Biopharma’s radiopharmaceutical prostate cancer treatment staved off disease progression or death by 3.5 months compared to hormone therapy in a closely watched Phase III …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
